BioNTech SE (NASDAQ:BNTX) Shares Sold by Legacy Wealth Asset Management LLC

Legacy Wealth Asset Management LLC lowered its stake in shares of BioNTech SE (NASDAQ:BNTX) by 2.3% during the fourth quarter, Holdings Channel reports. The fund owned 6,485 shares of the company’s stock after selling 156 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in BioNTech were worth $739,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. FMR LLC lifted its position in BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after buying an additional 5,598,190 shares during the period. Fred Alger Management LLC purchased a new position in BioNTech during the third quarter worth about $59,485,000. Point72 Asset Management L.P. lifted its position in BioNTech by 283.5% during the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after buying an additional 341,311 shares during the period. Braidwell LP purchased a new position in BioNTech during the third quarter worth about $29,425,000. Finally, New York State Common Retirement Fund lifted its position in BioNTech by 457.9% during the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock worth $25,900,000 after buying an additional 178,981 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Price Performance

BNTX stock opened at $111.93 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The firm has a market cap of $26.83 billion, a P/E ratio of -53.30 and a beta of 0.18. The stock has a 50-day simple moving average of $114.69 and a 200-day simple moving average of $104.41.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same quarter last year, the firm earned $0.73 EPS. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. On average, equities analysts predict that BioNTech SE will post -3.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BNTX. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their target price for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. TD Cowen cut their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Truist Financial began coverage on BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective on the stock. Finally, JPMorgan Chase & Co. cut their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a report on Tuesday, November 26th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.